Advertisement

Clinical Rheumatology

, Volume 31, Issue 5, pp 785–794 | Cite as

Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment

  • Sonia Mínguez
  • Irene Latorre
  • Lourdes Mateo
  • Alicia Lacoma
  • Jéssica Diaz
  • Alejandro Olivé
  • Jose Domínguez
Original Article

Abstract

Biological agents, particularly anti-Tumour Necrosis Factor (TNF)-α agents, have emerged as an effective treatment in patients with chronic inflammatory diseases. An association between anti-TNF-α antibodies and reactivation of latent tuberculosis infection (LTBI) has been established. Appropriate screening for TB infection has become mandatory before starting a treatment based on TNF-α inhibition. The objective was to determine the usefulness of IFN-γ release assays in diagnosing LTBI in patients with inflammatory rheumatic diseases scheduled for anti-TNF-α treatment. The study included 53 individuals with inflammatory rheumatism. All patients had a TST, a chest radiograph, QuantiFERON Gold In-Tube (QFN-G-IT) and T-SPOT.TB. To investigate the influence of non-tuberculous mycobacteria (NTM) infections on non-BCG-vaccinated patients, with a positive TST result and both negative IFN-γ assays, we performed an ex vivo ELISPOT, stimulating the cells separately with NTM sensitins. TST was positive in 7 cases, T-SPOT.TB in 11 and QFN-G-IT in 9 cases. Agreement between TST and T-SPOT.TB and QFN-G-IT was 77.35% (κ = 0.33 and κ = 0.40, respectively), and between both in vitro tests, it was 83.01% (κ = 0.57). Of the three patients with positive TST and negative T-SPOT.TB and QFN-G-IT, one positive ELISPOT result was obtained after stimulation with NTM sensitins. Positive TST, T-SPOT.TB and QFN-G-IT results were not affected by the immunosuppressive therapies. IFN-γ release assays are useful methods for avoiding TST false-positive results, but in those patients with a high risk of developing active TB and in the absence of predictive value studies in this specific kind of population for knowing how safe is the use of IGRAs alone, the combined use of TST and IFN-γ tests should be recommended in order to increase the overall number of LTBI diagnoses.

Keywords

Anti-TNF-α treatment IFN-γ release assays Rheumatic patients TST Tuberculosis 

Notes

Acknowledgements

We warmly thank the patients for agreeing to participate in the study. The manuscript has been revised by a native English speaker who is both a professional translator and qualified philologist from The Language Advisory & Translation Unit of the Servei de Llengües at the Universitat Autònoma de Barcelona (Spain). J. Dominguez is a researcher funded by the “Miguel Servet” programme of the Instituto de Salud Carlos III (Spain).

Disclosures

None of the investigators have any financial interest in or a financial conflict with the subject matter or materials discussed in this manuscript. This work was supported by grants from the Sociedad Española de Neumología y Cirugía Torácica, Societat Catalana de Pneumologia (SOCAP), Fundació Catalana de Pneumologia (FUCAP) and Societat Catalana de Reumatologia (SCR). None of the scientific societies nor Inverness Medical Ibérica SAU (Barcelona, Spain), Cellestis (Carnegie, Australia) or Oxford Immunotec (Abingdon, UK) had a role in the study design, implementation, data collection, management, analysis, interpretation of the data, preparation, review or approval of the manuscript.

References

  1. 1.
    Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P (2007) Crohn's disease: a review of current treatment with a focus on biologics. Drugs 67(17):2511–2537PubMedCrossRefGoogle Scholar
  2. 2.
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127PubMedCrossRefGoogle Scholar
  3. 3.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104PubMedCrossRefGoogle Scholar
  4. 4.
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3(3):148–155PubMedCrossRefGoogle Scholar
  5. 5.
    Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa M (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772PubMedCrossRefGoogle Scholar
  6. 6.
    Winthrop KL (2010) The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biological therapy. Int J Adv Rheumatol 8(2):43–52Google Scholar
  7. 7.
    Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17(6):968–975PubMedCrossRefGoogle Scholar
  8. 8.
    Jasmer RM, Nahid P, Hopewell PC (2002) Clinical practice. Latent tuberculosis infection. N Engl J Med 347(23):1860–1866PubMedCrossRefGoogle Scholar
  9. 9.
    Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV (2001) Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163(4):824–828PubMedGoogle Scholar
  10. 10.
    Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, Ewer K, Hill AV, Mehta A, Rodrigues C (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183(3):469–477PubMedCrossRefGoogle Scholar
  11. 11.
    Andersen P, Munk ME, Pollock JM, Doherty TM (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356(9235):1099–1104PubMedCrossRefGoogle Scholar
  12. 12.
    Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P (2004) Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 42(6):2379–2387PubMedCrossRefGoogle Scholar
  13. 13.
    Connell TG, Curtis N, Ranganathan SC, Buttery JP (2006) Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 61(7):616–620PubMedCrossRefGoogle Scholar
  14. 14.
    Dominguez J, Ruiz-Manzano J, De Souza-Galvao M, Latorre I, Mila C, Blanco S, Jimenez MA, Prat C, Lacoma A, Altet N, Ausina V (2008) Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 15(1):168–171PubMedCrossRefGoogle Scholar
  15. 15.
    Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361(9364):1168–1173PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328–1334PubMedCrossRefGoogle Scholar
  17. 17.
    Goletti D, Carrara S, Butera O, Amicosante M, Ernst M, Sauzullo I, Vullo V, Cirillo D, Borroni E, Markova R, Drenska R, Dominguez J, Latorre I, Angeletti C, Navarra A, Petrosillo N, Lauria FN, Ippolito G, Migliori GB, Lange C, Girardi E (2008) Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One 3(10):e3417PubMedCrossRefGoogle Scholar
  18. 18.
    Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV (2001) Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357(9273):2017–2021PubMedCrossRefGoogle Scholar
  19. 19.
    Domínguez J, Latorre I, Altet N, Mateo L, De Souza-Galvao M, Ruiz-Manzano J, Ausina V (2009) Interferon-gamma-release assays to diagnose TB infection in immunocompromised individual. Expert Rev Respir Med 3(3):309–327PubMedCrossRefGoogle Scholar
  20. 20.
    Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K (2005) Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 12(4):491–496PubMedGoogle Scholar
  21. 21.
    Domínguez J, De Souza-Galvao M, Ruiz-Manzano J, Latorre I, Prat C, Lacoma A, Milà C, Jiménez MA, Blanco S, Maldonado J, Altet N, Ausina V (2009) T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis 63:43–51PubMedCrossRefGoogle Scholar
  22. 22.
    Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P (2011) A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 91:260–267CrossRefGoogle Scholar
  23. 23.
    Lalvani A, Millington KA (2008) Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 8(2):147–152PubMedCrossRefGoogle Scholar
  24. 24.
    Domínguez J, Latorre I (2008) Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents. J Crohn's Colitis 2:250–254CrossRefGoogle Scholar
  25. 25.
    Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33(3):586–593PubMedCrossRefGoogle Scholar
  26. 26.
    Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, Codd MB, Dodd JD, Veale D, Fitzgerald O, Bresnihan B (2010) Comparison of interferon-{gamma}-release assays and conventional screening tests before tumour necrosis factor-{alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 69:181–185PubMedCrossRefGoogle Scholar
  27. 27.
    Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, Sandstede J, Frosch M, Tony HP, Kneitz C (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69(4):782–784PubMedCrossRefGoogle Scholar
  28. 28.
    Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y (2009) Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb) 89(2):136–141CrossRefGoogle Scholar
  29. 29.
    Girlanda S, Mantegani P, Baldissera E, Aiello P, Ratti M, Sabbadini MG, Fortis C (2010) ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol 29(10):1135–1141PubMedCrossRefGoogle Scholar
  30. 30.
    Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, Kaplan M, Dogru D, Yalcin E, Pekcan S, Kose M, Topaloglu R, Besbas N, Bakkaloglu A, Kiper N (2007) Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 11(11):1177–1182PubMedGoogle Scholar
  31. 31.
    Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A (2008) Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27(10):907–913PubMedCrossRefGoogle Scholar
  32. 32.
    Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, Marocco R, Lichtner M, Vullo V, Mastroianni CM (2010) Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeificiency virus infection and in patients candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 14(7):834–840PubMedGoogle Scholar
  33. 33.
    Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59(6):800–806PubMedCrossRefGoogle Scholar
  34. 34.
    Takahashi H, Shigehara K, Yamamoto M, Suzuki C, Naishiro Y, Tamura Y, Hirohashi Y, Satoh N, Shijubo N, Shinomura Y, Imai K (2007) Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27(12):1143–1148PubMedCrossRefGoogle Scholar
  35. 35.
    Latorre I, De Souza-Galvao M, Ruiz-Manzano J, Lacoma A, Prat C, Altet N, Ausina V, Dominguez J (2010) Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis. Eur Respir J 35:338–342PubMedCrossRefGoogle Scholar
  36. 36.
    Altet N, De Souza-Galvao M, Latorre I, Milà C, Jimenez MA, Solsona J, Cantos A, Zamora JJ, Ruiz-Manzano J, Ausina V, Dominguez J (2011) Diagnosing TB infection in children: analysis of discordances using in vitro tests and tuberculin skin test. Eur Respir J 37:1166–1174CrossRefGoogle Scholar
  37. 37.
    Informe sobre la situación de la tuberculosis. Red Nacional de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. España, 2010.Google Scholar
  38. 38.
    Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez J, García JM, Vidal R (2008) SEPAR guidelines. Diagnostic and treatment of tuberculosis. Arch Bronconeumol 44:551–566PubMedCrossRefGoogle Scholar
  39. 39.
    Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159(1):15–21PubMedGoogle Scholar
  40. 40.
    Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67(1):84–90PubMedCrossRefGoogle Scholar
  41. 41.
    Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ (2008) Usefulness of enzyme-linked immunospot assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 35(7):1271–1276PubMedGoogle Scholar
  42. 42.
    Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776–781PubMedGoogle Scholar
  43. 43.
    Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, Thomsen VO, Jensen DV, Koch A, Wohlfahrt J, Ravn P (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36(9):1876–1884PubMedCrossRefGoogle Scholar
  44. 44.
    Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Larsen I, Ravn P (2011) Prednisolone treatment affects the performance of the QuantiFERON Gold In-Tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. doi: 10.1002/ibd.21605
  45. 45.
    Greenberg JD, Reddy SM, Schloss SG, Kurucz OS, Bartlett SJ, Abramson SB, Bingham CO 3rd (2008) Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 35(5):770–775PubMedGoogle Scholar
  46. 46.
    Chee CB, Khinmar KW, Gan SH, Barkham TM, Pushparani M, Wang YT (2007) Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175(3):282–287PubMedCrossRefGoogle Scholar
  47. 47.
    Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH (2010) IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect 61(2):133–143PubMedCrossRefGoogle Scholar
  48. 48.
    Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME (2009) Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 36(3):546–551PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Sonia Mínguez
    • 1
  • Irene Latorre
    • 2
  • Lourdes Mateo
    • 1
  • Alicia Lacoma
    • 2
  • Jéssica Diaz
    • 2
  • Alejandro Olivé
    • 1
  • Jose Domínguez
    • 2
  1. 1.Servei de Reumatologia, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació en Ciències de la Salut Germans Trias i PujolUniversitat Autònoma de BarcelonaBadalonaSpain
  2. 2.Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d’Investigació en Ciències de la Salut Germans Trias i PujolUniversitat Autònoma de Barcelona, CIBER Enfermedades Respiratorias. Institut de Salud Carlos IIIBadalonaSpain

Personalised recommendations